Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma

The proposed study is an open-label, single arm phase II study of venetoclax in combination with rituximab in patients over the age of 60 with previously untreated mantle cell lymphoma. The primary objective of the trial is to determine whether the combination of venetoclax with rituximab in this patient population yields a clinically acceptable proportion of overall responses (ORR, assessed by PET/CT with Lugano criteria) without chemotherapy.

Study Overview

• Status: Recruiting
• Conditions: Mantle Cell Lymphoma
• Intervention / Treatment: Drug: Venetoclax Oral Tablet [Venclexta]

Detailed Description

For young, fit patients with mantle cell lymphoma, intensive chemotherapy and rituximab followed by ASCT is often used to achieve prolonged disease free survival. However, this therapy is not curative and has not been shown to improve overall survival. For older or frail patients, who are ineligible for stem cell transplantation, improved disease free survival can be achieved with chemotherapy and rituximab without ASCT, but at the cost of significant short and long-term toxicity. Venetoclax monotherapy has shown impressive single-agent activity in relapsed and refractory mantle cell lymphoma with low rates of adverse events.

The hypothesis is that initial therapy with venetoclax and rituximab will result in rates of CR and PR that are comparable to historical rates with chemoimmunotherapy. Furthermore, this regimen will have fewer side effects than traditional therapy. Investigators also hypothesize that patients achieving a CR will have long durations of response that will continue after stopping venetoclax.

Study investigators will test this hypothesis with an open label, single arm phase II trial with a target accrual of 40 participants. This study will include patients over age 60 who are not candidates for aggressive upfront therapy . Subjects will receive venetoclax and rituximab for up to 12 cycles of 4 weeks each. All patients will stop venetoclax after 12 cycles. Participants who have stable disease or disease progression after 4 cycles will be removed from the trial in order to receive standard of care chemoimmunotherapy. Participants who do not achieve a CR after 8 cycles of venetoclax and rituximab will receive 4 cycles of standard of care bendamustine in addition to continuing rituximab and venetoclax.

This is the first phase II study of venetoclax and rituximab alone as initial therapy for mantle cell lymphoma. In the relapsed and refractory setting, venetoclax has shown high activity in MCL, and as such is a promising option for a non-chemotherapy approach to upfront treatment.

• Study Type: Interventional
• Enrollment (Estimated): 40
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Phirun Mindel; Phone Number: 443-287-0388; Email: mailto:pvang1@jhmi.edu

Study Locations

• United States
  • Maryland
    • Baltimore, Maryland, United States, 21231
      • Recruiting
      • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
      • Contact: Lode Swinnen, MD; Phone Number: 410-614-6398; Email: lswinne1@jhmi.edu
      • Contact: Phirun Mindel, RN; Phone Number: 4432870388; Email: pvang1@jhmi.edu

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 60 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Subjects must have a histologically confirmed diagnosis of mantle cell lymphoma as defined by the World Health Organization (WHO) classification scheme.
• Age ≥ 60
• Subjects must be previously untreated for mantle cell lymphoma and deemed to require treatment by the treating physician
• ECOG performance status of 0-3

• Subject must have adequate bone marrow* without growth factor support as follows:

  • Absolute Neutrophil Count (ANC) ≥ 1000/μL
  • Platelets ≥ 75,000/mm3 (entry platelet count must be independent of transfusion within 14 days of Screening)
  • Hemoglobin ≥ 9.0 g/dL * These criteria may be waived by study investigators if there is evidence of bone marrow involvement by MCL that is believed to be the cause of the cytopenias.

• Subject must have adequate renal, and hepatic function, per laboratory reference range at screening as follows:

  • Subject must have adequate renal, and hepatic function, per laboratory reference range at screening as follows:
  • Calculated creatinine clearance ≥ 40 mL/min; determined via the Cockcroft-Gault formula.

  • AST and ALT ≤ 3.0 × ULN; Bilirubin ≤ 1.5 × ULN*. Subjects with Gilbert's Syndrome may have a bilirubin > 1.5 × ULN

    • These criteria may be waived by study investigators if abnormal values believed to be due to lymphoma.

• Female subjects must be surgically sterile, postmenopausal (for at least 1 year), or have negative results for a pregnancy test performed as follows:

  • At Screening on a serum sample obtained within 14 days prior to the first study drug administration, and
  • Prior to dosing on a urine sample obtained on Cycle 1 Day 1 if it has been > 7 days since obtaining the serum pregnancy test results.

  • All female subjects not surgically sterile or postmenopausal (for at least 1 year) and non-vasectomized male subjects must practice at least 1 of the following methods of birth control:

    1. Total abstinence from sexual intercourse (minimum 1 complete menstrual cycle);
    2. A vasectomized partner(s);
    3. Hormonal contraceptives (oral, parenteral, vaginal ring or transdermal) for at least 3 months prior to study drug administration;
    4. Double-barrier method (condoms and diaphragm with spermicidal [sponge, jellies or creams]).
• Ability to understand and willingness to sign IRB-approved informed consent

Exclusion Criteria:

• Subject has blastoid-variant mantle cell lymphoma
• Subject requires immediate cytoreduction as determined by study investigators
• Subject has documented CNS involvement of mantle cell lymphoma
• Subject has Ann Arbor stage I or contiguous stage II mantle cell lymphoma
• Subject has an uncontrolled infection
• Subject has HIV infection
• All subjects will be screened for Hepatitis B (HBsAg, anti-HBs, anti-HBc IgM and total) and Hepatitis C (antibody or RNA). Subjects who are positive for Hepatitis B by HBsAg or DNA as well as subjects positive for Hepatitis C will be excluded. Subjects with anti-HBc positivity and DNA negative may be included but will be required to undergo monthly HBV DNA testing and liver function liver function testing (AST, ALT, alkaline phosphatase, total bilirubin). Patients with HCV antibody positivity and HCV pcr negativity are eligible to be included.
• Subject requires the use of warfarin
• Subject has received immunization with live virus vaccine within 28 days prior to the first dose of study drug
• A female subject is pregnant or breast-feeding

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: venetoclax and rituximab in patients over 60 yrs old with previously untreated mantle cell lymphoma; Venetoclax dose escalation for Cycles 1-4. If Complete response (CR) at Cycle 4, continue with cycles 5-12 at fixed venetoclax 400mg dose. If partial response (PR) at Cycle 4, continue with cycles 5-8 at fixed venetoclax 800mg dose. If CR at Cycle 8 after PR, continue with cycles 9-12 at fixed venetoclax 800mg dose. If continued PR at Cycle 8, reduce venetoclax to 400mg and add bendamustine 90 mg/m2.

Drug: Venetoclax Oral Tablet [Venclexta]; Sequential dose levels for Venetoclax dependent on patient response. Fixed doses of 375 mg/m2 rituximab. Fixed dose of Bendamustine 90 mg/m2 added for those with continued PR at Cycle 8; Other Names: rituximab infusion [Rituxan]; Bendamustine infusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall response rate (ORR) after four cycles of venetoclax and rituximab.	The ORR will be the sum of complete (CR) and partial responses (PR)as determined by PET/CT and Lugano criteria. Simon's optimal two-stage design will be used to test the null hypothesis that the true ORR is 50% or less (not considered clinically acceptable).	120 days

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Proportion of CR	Proportion of CR as determined by PET/CT and Lugano criteria after four cycles	120 days
Proportion of PR	Proportion of PR as determined by PET/CT and Lugano criteria after four cycles	120 days
Proportion of stable disease	Proportion of stable disease as determined by PET/CT and Lugano criteria after four cycles	120 days
Proportion of disease progression	Proportion of disease progression as determined by PET/CT and Lugano criteria after four cycles	120 days
Rate of CR after 8 cycles of venetoclax and rituximab	Rate of CR as determined by PET/CT and Lugano criteria after 8 cycles of venetoclax and rituximab	240 days
Rate of PR after 8 cycles of venetoclax and rituximab	Rate of PR as determined by PET/CT and Lugano criteria after 8 cycles of venetoclax and rituximab	240 days
Proportion of progression free survival (PFS)	To evaluate the progression free survival (PFS) in the intent to treat (ITT) population	240 days
free survival (PFS)	To evaluate the progression free survival (PFS) in the intent to treat (ITT) population	240 days
overall survival (OS)	To evaluate the overall survival (OS) in the intent to treat (ITT) population	240 days
duration of response (DOR)	To evaluate the duration of response (DOR) for participants achieving a CR or PR	240 days

Collaborators and Investigators

• Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
• Collaborators: AbbVie
• Investigators: Principal Investigator: Lode Swinnen, MD, Johns Hopkins School of Medicine

Study record dates

Study Major Dates

• Study Start (Actual): June 21, 2022
• Primary Completion (Estimated): September 15, 2025
• Study Completion (Estimated): September 15, 2026

Study Registration Dates

• First Submitted: August 26, 2021
• First Submitted That Met QC Criteria: August 26, 2021
• First Posted (Actual): August 27, 2021

Study Record Updates

• Last Update Posted (Actual): July 5, 2023
• Last Update Submitted That Met QC Criteria: June 30, 2023
• Last Verified: June 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Lymphoma, Non-Hodgkin; Lymphoma; Lymphoma, Mantle-Cell; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Alkylating Agents; Venetoclax; Bendamustine Hydrochloride
• Other Study ID Numbers: J2146; IRB00288478 (Other Identifier: JHM IRB)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No